Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating expenses:
Research and development	$ 20,337	$ 14,904
General and administrative	10,927	12,908
In-process R&D	50,618	0
Total operating expenses	81,882	27,812
Loss from operations	(81,882)	(27,812)
Other expense	(299)	(1,656)
Loss before income tax expense	(82,181)	(29,468)
Income tax expense	0	(32)
Net loss	$ (82,181)	$ (29,500)
Net loss per share - basic and diluted	$ (1.31)	$ (0.96)
Basic and diluted weighted average shares outstanding	62,870	30,776